Clinical Trial Update: Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of lenalidomide (Revlimid), melphalan, and dexamethasone as first-line therapy for multiple myeloma was terminated, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Melphalan (Melphalan)
• Revlimid (lenalidomide)

Snippet

Sponsor: NYU Langone Health | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2013-10-18